IDH2 and neoplasm: This strategy might be a welcome contribution for the treatment of IDH-mutated neoplasms for several reasons, including the notion that IDH inhibitors might not be efficient in every patient with an IDH mutation and the concern of targeting a mutated enzyme that confers a better prognosis.